Skip to main content

OncoDNA Inks Exclusive Distribution Deal with BioSequence

NEW YORK (GenomeWeb) – Belgium-based OncoDNA today announced it has reached a distribution agreement with BioSequence, a Spanish personalized cancer genomics firm.

Under the terms of the agreement, BioSequence will become the exclusive Spanish distributor of OncoDNA's clinical oncology molecular diagnostics. OncoDNA offers OncoDeep Dx, which links specific genes to targeted cancer treatments, as well as other clinical cancer panels to measure translocations and protein presence and activity.

"BioSequence is a partner of choice to improve OncoDeep's use and awareness in Spain," Michäel Herman, OncoDNA's business development manager, said in a statement.

"We were very impressed by the OncoShare web platform," which offers clinicians clinically relevant interpretations of tumors sequencing results, said Adriana Terrádez, BioSequence's business development manager.

OncoDNA is affiliated with the Institute of Pathology and Genetics in Belgium.

In September 2014, OncoDNA signed an exclusive distribution deal in Greece with Istomedica.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.